Pacific Biosciences Delivers Enhanced DNA Sequencing Chemistry and Software to Help Solve Complex Genetic Problems

Pacific Biosciences Delivers Enhanced DNA Sequencing Chemistry and Software to
Help Solve Complex Genetic Problems

Average Read Lengths of 5,000 Bases and Reads as Long as 20,000; PacBio
Hosting Workshop at ASHG Annual Meeting

MENLO PARK, Calif., Nov. 6, 2012 (GLOBE NEWSWIRE) -- Pacific Biosciences of
California, Inc. (Nasdaq:PACB) provider of the PacBio^® RS High Resolution
Genetic Analyzer, today announced the latest enhancements to its DNA
sequencing system, the XL release featuring new chemistry and software for
extraordinarily long read lengths that average 5,000 bases.

Pacific Biosciences' Single Molecule, Real-Time (SMRT^®) sequencing generates
reads an order of magnitude longer than other leading DNA sequencing
technologies. With the latest advance, the average read length increases 67
percent from 3,000 to 5,000 bases, with some reads as long as 20,000 bases.
Long reads are critical for resolving genetic complexity in applications such
as the assembly and finishing of genomes, phasing genomic variation over long
distances, understanding human nucleotide repeat disorders, and resolving the
structure of alternatively spliced transcripts.

The new XL release provides increased read lengths through a combination of
chemistry and software. The new chemistry includes a faster polymerase that
reads more bases per second. This release also includes the Stage Start
feature, which produces longer reads by enabling sequence data collection to
begin when the polymerase is activated. Additionally, PacBio has increased the
length of time the instrument can record data during the sequencing reaction,
also contributing to an increase in read lengths.

"The XL release is an enhancement to our existing C2 chemistry to address
applications that require the longest reads, like de novo assembly," said Dr.
Jonas Korlach, Chief Scientific Officer of Pacific Biosciences. "A unique
characteristic of our SMRT sequencing technology is the ability to tune the
experimental design to maximize results for the project's application and
goals. Through this flexibility and our continued performance enhancements,
our customers can carry out their current research projects more efficiently,
and engage in new applications to help resolve very complex genomes and
transcriptomes."

The utility of the latest upgrade was demonstrated by scientists at Cold
Spring Harbor Laboratory who were trying to assemble the complex rice genome.
The new chemistry produced 9x coverage with long reads — 50% of the data came
from reads 4,800 base pairs or longer. Commenting on the results, Assistant
Professor Dr. Mike Schatz at Cold Spring Harbor said, "Adding the long reads
from PacBio doubled the contig connectivity over the current state-of-the-art
ALLPATHS-LG assembler and mate-pair recommendations."

Dr. Korlach will discuss the latest enhancements to the PacBio RS in a
workshop at the American Society for Human Genetics (ASHG) Annual Meeting in
San Francisco on November 8 at 12:45 p.m. Also speaking to share their
successes using the PacBio RS are customers Dr. Paul Hagerman from UC Davis
School of Medicine ("Sequencing the Unsequenceable: Expanded CGG-repeat
Alleles of the Fragile X Gene"), Dr. Hagen Tilgner, Stanford University
Department of Genetics ("Eukaryotic Transcriptome Analysis Using PacBio"), and
Dr. David Witherspoon, University of Utah Department of Human Genetics
Sequencing ("Mobile-Element Scanning (ME-Scan) of Active LINE-1 Elements in
Humans using Single Molecule, Real-Time (SMRT) Sequencing").

Attendees at the ASHG Annual Meeting can visit any of the workshop sessions
taking place from 12:45-2:15 p.m. and visit the PacBio booth (#610). Those not
attending the meeting can register to view recordings of the workshop sessions
on the company's website. For more information, please visit www.pacb.com.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (Nasdaq:PACB) offers the PacBio^® RS
High Resolution Genetic Analyzer to help scientists solve genetically complex
problems. Based on its novel Single Molecule, Real-Time (SMRT^®) technology,
the company's products enable: targeted sequencing to more comprehensively
characterize genetic variations; de novo genome assembly to more fully
identify, annotate and decipher genomic structures; and DNA base modification
identification to help characterize epigenetic regulation and DNA damage. By
providing access to information that was previously inaccessible, Pacific
Biosciences enables scientists to increase their understanding of biological
systems.

CONTACT: Media:
         Maurissa Messier
         For Pacific Biosciences
         760.539.7417
         maurissa@bioscribe.com
        
         Investors:
         Trevin Rard
         Pacific Biosciences
         650.521.8450
         ir@pacificbiosciences.com